Orexigen Therapeutics Inc
Most Recent
How Much Potential Does Saxenda Hold for Novo?
Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.
Most Recent
Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.